DENNIS D. KIM - 13 Apr 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Paul Quinlan, as attorney-in-fact for Dennis D. Kim
Issuer symbol: N/A
Transactions as of: 13 Apr 2023
Net transactions value: -$616,016
Form type: 4
Filing time: 17 Apr 2023, 19:24:09 UTC
Previous filing: 30 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CBAY	Common Stock	Options Exercise	$34,003	+7,781	+39%	$4.37	27,781	13 Apr 2023	Direct
transaction	CBAY	Common Stock	Sale	$69,880	-7,781	-28%	$8.98	20,000	13 Apr 2023	Direct	F1
transaction	CBAY	Common Stock	Options Exercise	$490,397	+112,219	+561%	$4.37	132,219	17 Apr 2023	Direct
transaction	CBAY	Common Stock	Sale	$1,070,536	-112,219	-85%	$9.54	20,000	17 Apr 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-7,781	-2.7%	$0.000000	282,119	13 Apr 2023	Common Stock	7,781	$4.37	Direct	F3
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-112,219	-40%	$0.000000	169,900	17 Apr 2023	Common Stock	112,219	$4.37	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter.